Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00440908 · ClinicalTrials.gov registry record
Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers
A clinical trial of Inflammation and End Stage Renal Disease, sponsored by Fresenius Medical Care North America.
- Completed
- Registry status
- 2,500
- Enrollment target
- 2
- Study locations
NCT00440908 is a study of Inflammation and End Stage Renal Disease that has completed, run by Fresenius Medical Care North America. The registered enrollment target is 2,500 participants, above the 269-participant average among 132 other Inflammation trials with a reported enrollment target (829% higher). The trial reports 2 study locations across 1 state.
The verdict
NCT00440908, a study of Inflammation and End Stage Renal Disease, has completed, sponsored by Fresenius Medical Care North America.
- COMPLETED
- Registry status
- 2,500 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study is a prospective cohort trial utilizing sequential laboratory results from excess serum obtained from hemodialysis patients (acting as their own controls). The objective of this study is to determine the impact of converting from reuse to single use of dialyzers on specific markers of nutrition (pre-albumin) and inflammation (CRP) in hemodialysis patients followed over a period of 6-months after conversion. The Hypothesis is: Comparing values obtained at baseline to values at the end of 6-months after conversion from reuse to single use in the same patients: 1. In patients with baseline CRP \> 5 mg/L: Mean decrease of 5 mg/L 2. In patients with baseline CRP \< 5 mg/L: \> 95% will remain \< 5 mg/L 3. Mean serum pre-albumin levels will increase by at least 3 mg/dL. The study population will be drawn from \~2,900 patients that are currently undergoing hemodialysis in 48 dialysis units that have been identified as continuing to reuse dialyzers and specifically are using a peracetic acid-based disinfectant (Renalin®), as of February 1, 2007. These facilities will be scheduled to convert to single use of dialyzers between May and December, 2007. The selection of patients will depend solely on the facility conversion date, on a first-come, first-served basis. All patients within the dialysis facility that provide blood specimen for their routine monthly lab draws will be eligible. The facilities and patients will be enrolled consecutively until the desired sample size of approximately 2,500 patients is reached
Conditions Studied
Study Locations (2)
Massachusetts
- Fresenius Medical Care North America - Waltham
- Fresenius Medical Care North America - Waltham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,500 participants |
| Start Date | 2007-03 |
| Est. Completion | 2007-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00440908
The ClinicalTrials.gov registry entry for NCT00440908 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 269-participant average among 132 other Inflammation trials with a reported enrollment target (829% higher). The listed sponsor is Fresenius Medical Care North America, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Inflammation appearing as the primary indexed condition, and to 0 interventions.
NCT00440908 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00440908 about?
NCT00440908 is a clinical study titled "Inflammation and Nutritional Parameters in Hemodialysis Patients Using Reprocessed Dialyzers". The study is a prospective cohort trial utilizing sequential laboratory results from excess serum obtained from hemodialysis patients (acting as their own controls). The objective of this study is to determine the impact of converting from reuse to single use of dialyzers on specific markers of nutr...
What is the current status of trial NCT00440908?
This trial is currently completed. The enrollment target is 2,500 participants. The study started on 2007-03. Estimated completion is 2007-12.
What conditions does trial NCT00440908 study?
This clinical trial studies the following conditions: Inflammation, End Stage Renal Disease.
Who is sponsoring clinical trial NCT00440908?
This trial is sponsored by Fresenius Medical Care North America, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00440908 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Inflammation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketone Ester And Salt (KEAS) in Older Adults
RECRUITING · NA
-
Reducing Suicide Risk Among Aging Caregivers of Persons With AD/ADRD
RECRUITING · NA
-
Reducing Frailty for Older Cancer Survivors Using Supplements II
RECRUITING · Phase 2
-
The Iowa ACEs and Sleep Cohort and Manipulating Sleep in Young Adults With ACEs Studies
RECRUITING · NA
-
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RECRUITING · Phase 3
-
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.